Dysphagia as a symptom of an adverse effect of anticoagulant therapy

Czech version

Authors: Kolářová R.
Authors‘ workplace: Endoskopické centrum, Oblastní nemocnice Náchod a. s.
Published in: Gastroent Hepatol 2019; 73(4): 336-338
Category: Clinical and Experimental Gastroenterology: Case Report
doi: https://doi.org/10.14735/amgh2019336

Overview

This case report presents an unusual side effect of dabigatran that can lead to drug-related esophageal mucosal involvement, known as dabigatran-induced esophagitis, manifested by dysphagic problems and typical endoscopic findings, especially in predisposed patients. After discontinuation of dabigatran, clinical problems rapidly resolved and endoscopic findings normalized.

Doručeno/Submitted: 3. 6. 2019

Přijato/Accepted: 23. 7. 2019

MUDr. Renata Kolářová

Endoskopické centrum

Oblastní nemocnice Náchod a. s.

Purkyňova 446

547 01 Náchod

kolarova.renata@nemocnicenachod.cz

Konfl ikt zájmů: Autorka deklaruje, že text článku odpovídá etickým standardům, byla dodržena anonymita pacientů a prohlašuje, že v souvislosti s předmětem článku nemá
fi nanční, poradenské ani jiné komerční zájmy.
Publikační etika: Příspěvek nebyl dosud publikován ani není v současnosti zaslán do jiného časopisu pro posouzení. Autorka souhlasí s uveřejněním svého jména a e-mailového
kontaktu v publikovaném textu.
Dedikace: Článek není podpořen grantem ani nevznikl za podpory žádné společnosti.
Redakční rada potvrzuje, že rukopis práce splnil ICMJE kritéria pro publikace zasílané do biomedicínských časopisů.
Confl ict of Interest: The author declares that the article/manuscript complies with ethical standards, patient anonymity has been respected, and she states that she has no
fi nancial, advisory or other commercial interests in relation to the subject matter.
Publication Ethics: This article/manuscript has not been published or is currently being submitted for another review. The authors agree to publish their name and e-mail in
the published article/manuscript.
Dedication: The article/manuscript is not supported by a grant nor has it been created with the support of any company.
The Editorial Board declares that the manuscript met the ICMJE „uniform requirements“ for biomedical papers.

Keywords:

bleeding – esophagitis – dysphagia

Sources

1. Duda M, Hildebrand T. Jícen a kardie. In: Mařatka Z et al. Gastroenterologie. 1. vyd. Praha: Karolinum 1999: 53–54.

2. Ootani A, Hayashi Y, Miyagi Y. Dabigatran-induced esophagitis. Clin Gastroenterol Hepatol 2014; 12 (7): e55–e56. doi: 10.1016/j.cgh.2013.09.010.

3. Matsuura H, Suto K, Yasuhara H et al. Longitudinal sloughing mucosal casts: dabigatran-induced oesophagitis. Eur Heart J 2018; 39 (36): 3400. doi: 10.1093/eurheartj/ehy538.

4. Singh S, Savage L, Klein M et al. Severe necrotic oesophageal and gastric ulceration associated with dabigatran. BMJ Case Rep 2013. bcr2013009139. doi: 10.1136/bcr-2013-009139.

5. Wood M, Shaw P. Pradaxa-induced esophageal ulcer. BMJ Case Rep 2015. bcr2015211371. doi: 10.1136/bcr-2015-211371.

6. Kajihara Y. Dabigatran-induced esophagitis. Cleve Clin J Med 2019; 86 (5): 303–304. doi: 10.3949/ccjm.86a.18117.

7. Kajihara Y. Exfoliative esophagitis. Eur J Intern Med 2018; 53: e1. doi: 10.1016/j.ejim.2017.12. 013.

8. European Medicine Agency. SPC Pradaxa. [online]. Dostupné na: https: //www.ema.europa.eu/en/documents/product-information/pradaxa-epar-product-information_cs.pdf.

9. Nyuzuki S, Yamakawa R, Kawauchi K et al. Clinical study of esophagitis induced by dabigatran. [online]. Available from: https: //cdn.ueg.eu/uegfolga-web/uegf-ep-mat088/P1039.pdf.

10. Toya Y, Nakamura S, Tomita K et al. Dabigatran-induced esophagitis: the prevalence and endoscopic characteristics. J Gastroenterol Hepatol 2016; 31 (3): 610–614. doi: 10.1111/jgh.13 024.

11. Katzka DA. Esophageal disorders caused by medications, trauma, and infection. In: Feldman M, Friedman LS, Brandt LJ (eds). Sleisenger and Fordtran’s gastrointestinal and liver disease. 9th ed. Philadelphia: Saunders/Elsevier 2010: 735–737.